INT22275

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.54
First Reported 1982
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 25
Total Number 25
Disease Relevance 8.67
Pain Relevance 7.34

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (TBXA2R) signal transducer activity (TBXA2R)
Anatomy Link Frequency
platelet 7
PRP 3
nasal 1
plaque 1
kidney 1
TBXA2R (Homo sapiens)
Pain Link Frequency Relevance Heat
COX-2 inhibitor 75 100.00 Very High Very High Very High
antagonist 6 100.00 Very High Very High Very High
qutenza 10 99.98 Very High Very High Very High
aspirin 94 99.80 Very High Very High Very High
bradykinin 14 99.52 Very High Very High Very High
cINOD 293 97.92 Very High Very High Very High
Analgesic 29 95.24 Very High Very High Very High
Inflammation 140 94.28 High High
depression 3 93.96 High High
agonist 20 93.28 High High
Disease Link Frequency Relevance Heat
Rhinitis 125 99.92 Very High Very High Very High
Cough 30 99.64 Very High Very High Very High
Thrombosis 18 99.16 Very High Very High Very High
Hypertension 5 98.90 Very High Very High Very High
Edema 4 98.72 Very High Very High Very High
Hemorrhage 40 97.64 Very High Very High Very High
INFLAMMATION 192 97.20 Very High Very High Very High
Depression 3 93.96 High High
Headache 6 92.48 High High
Cv Unclassified Under Development 4 91.32 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Further, patients on ACE inhibitors who develop cough may benefit from TXA2 synthetase inhibitors.
Negative_regulation (inhibitors) of TXA2 associated with cough
1) Confidence 0.54 Published 1997 Journal Life Sci. Section Abstract Doc Link 9126880 Disease Relevance 0.86 Pain Relevance 0.07
N-Carboxy-3-morpholinosydnone imine ethyl ester (molsidomine) and its main metabolite 3-morpholinosydnone imine (SIN-1) were investigated in rabbit platelet-rich plasma (PRP) for antiaggregatory activity and inhibition of thromboxane A2 (TXA2) generation (arachidonic acid (AA)-induced) as well as in human PRP regarding prostaglandin endoperoxide analogue (U-46 619)- and AA-induced aggregation and TXB2 formation.
Negative_regulation (inhibition) of thromboxane A2 in PRP
2) Confidence 0.45 Published 1982 Journal Arzneimittelforschung Section Abstract Doc Link 6896278 Disease Relevance 0 Pain Relevance 0
N-Carboxy-3-morpholinosydnone imine ethyl ester (molsidomine) and its main metabolite 3-morpholinosydnone imine (SIN-1) were investigated in rabbit platelet-rich plasma (PRP) for antiaggregatory activity and inhibition of thromboxane A2 (TXA2) generation (arachidonic acid (AA)-induced) as well as in human PRP regarding prostaglandin endoperoxide analogue (U-46 619)- and AA-induced aggregation and TXB2 formation.
Negative_regulation (inhibition) of TXA2 in PRP
3) Confidence 0.45 Published 1982 Journal Arzneimittelforschung Section Abstract Doc Link 6896278 Disease Relevance 0 Pain Relevance 0
The inhibitory effect of ruthenium red and capsaicin on the bradykinin response may be due to inhibition of thromboxane A2 release or arachidonic mobilisation.
Negative_regulation (inhibition) of thromboxane A2 associated with qutenza and bradykinin
4) Confidence 0.42 Published 1995 Journal Eur. J. Pharmacol. Section Abstract Doc Link 7545124 Disease Relevance 0 Pain Relevance 0.62
To 11 patients with hypertension, who had developed cough induced by ACE inhibitors, a TXA2 synthetase inhibitor, ozagrel was given for 1 to 2 months together with the ACE inhibitors.
Negative_regulation (inhibitor) of TXA2 associated with hypertension and cough
5) Confidence 0.40 Published 1997 Journal Life Sci. Section Abstract Doc Link 9126880 Disease Relevance 0.70 Pain Relevance 0.09
Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors.
Negative_regulation (inhibition) of Thromboxane A2 associated with cough
6) Confidence 0.39 Published 1997 Journal Life Sci. Section Title Doc Link 9126880 Disease Relevance 0.77 Pain Relevance 0.08
Mediation of these effects by thromboxane A2 (TXA2) inhibition was discounted since under the same experimental conditions, adrenaline did not stimulate TXA2 synthesis and A23187-stimulated TXA2 synthesis was only marginally inhibited by concentrations of ibuprofen and indomethacin that inhibited 45Ca2+ uptake by 50%.
Negative_regulation (inhibition) of thromboxane A2
7) Confidence 0.37 Published 1990 Journal Eur. J. Pharmacol. Section Abstract Doc Link 2272350 Disease Relevance 0.07 Pain Relevance 0.23
They had (i) negative fractional lactate extraction; (ii) pacing-induced decreases of plasma thromboxane A2 levels in the coronary sinus blood (564 +/- 57 versus 479 +/- 47 ng/l, P < 0.05) at 2 min of peak-pacing; the data increased at 10 min of peak-pacing (564 +/- 57 versus 620 +/- 60 ng/l, P < 0.05), then returned to baseline levels at 5 and 10 min post-pacing; (iii) significantly increased lipid peroxides on low-density lipoprotein of the coronary sinus blood at 2 and 10 min of peak-pacing (each P < 0.001), as well as at 5 min post-pacing (P < 0.05); (iv) significant correlation between thromboxane A2 levels and lipid peroxides on low-density lipoprotein of the coronary sinus blood samples. 3.
Negative_regulation (decreases) of thromboxane A2 in plasma
8) Confidence 0.34 Published 1998 Journal Clin. Sci. Section Abstract Doc Link 9505863 Disease Relevance 0.50 Pain Relevance 0.17
Cardiovascular side effects have been found in selective COX-2 inhibitors (Rahman and Khan, 2004; Singh, 2004; Solomon et al, 2005), presumably due to the decrease in PGI2/TXA2.
Negative_regulation (decrease) of TXA2 associated with cox-2 inhibitor
9) Confidence 0.33 Published 2008 Journal Mol Syst Biol Section Body Doc Link PMC2673713 Disease Relevance 0.44 Pain Relevance 0.45
In our simulation, the value of PGI2/TXA2 was observed to decrease.
Negative_regulation (value) of TXA2
10) Confidence 0.24 Published 2008 Journal Mol Syst Biol Section Body Doc Link PMC2673713 Disease Relevance 0.46 Pain Relevance 0.39
Because of differential requirements for the inhibition of thromboxane A2 versus PGI2 biosynthesis in vivo, most traditional nonsteroidal anti-inflammatory drugs tend to mimic the effects of coxibs, rather than aspirin, on prostanoid-dependent cardiovascular homeostasis.
Negative_regulation (inhibition) of thromboxane A2 associated with aspirin, inflammation and cinod
11) Confidence 0.23 Published 2006 Journal J. Cardiovasc. Pharmacol. Section Abstract Doc Link 16785823 Disease Relevance 0.19 Pain Relevance 0.24
Disruption of the integrity of atheromatous plaque architecture adds to the vulnerability for in situ thrombus formation, and it has been suggested that combined inhibition of COX-2 and TXA2 could be detrimental to plaque stability [23,30].
Negative_regulation (inhibition) of TXA2 in plaque associated with thrombosis
12) Confidence 0.13 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1860062 Disease Relevance 0.31 Pain Relevance 0.13
Eugenol and capsaicin inhibited thromboxane B2 (TXB2) formation in platelets in a dose-dependent manner challenged with AA apparently by the inhibition of the cyclooxygenase (COX-1).
Negative_regulation (inhibited) of thromboxane B2 in platelets associated with qutenza
13) Confidence 0.12 Published 2009 Journal Prostaglandins Leukot. Essent. Fatty Acids Section Abstract Doc Link 19501497 Disease Relevance 0.10 Pain Relevance 0.64
TXA2 failed to reverse COX-2 inhibitor-mediated downregulation of 27-hydroxylase and ABCA1
Negative_regulation (downregulation) of TXA2 associated with cox-2 inhibitor
14) Confidence 0.09 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1860062 Disease Relevance 0 Pain Relevance 0.17
Platelet inhibition by Aspirin results from the irreversible inhibition of cyclooxygenase-1 enzyme and prevention of thromboxane A2, a potent aggregatory agent, formation.
Negative_regulation (inhibition) of thromboxane A2 in Platelet associated with aspirin
15) Confidence 0.09 Published 2008 Journal Cardiovascular & hematological disorders drug targets Section Abstract Doc Link 19075637 Disease Relevance 0.56 Pain Relevance 0.56
TXA 2 receptor antagonists have been shown to reduce allergen induced nasal mucosal swelling in patients with AR.
Negative_regulation (reduce) of TXA 2 receptor in nasal associated with rhinitis, antagonist and edema
16) Confidence 0.04 Published 2010 Journal Clin Mol Allergy Section Body Doc Link PMC2835646 Disease Relevance 1.36 Pain Relevance 0.29
Thus, naproxen is associated with profound inhibition of prostacyclin but the possible CV hazard associated with this effect may be mitigated by a parallel profound and persistent suppression of platelet TXA2 (Capone et al 2004), which translates into a small CV protection or neutral effect (Hernández-Díaz et al 2006; Kearney et al 2006).
Negative_regulation (suppression) of TXA2 in platelet
17) Confidence 0.03 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621416 Disease Relevance 0.15 Pain Relevance 0.36
These findings indicate that PGE2 and thromboxane B2 inhibition can be used to predict and select efficacious doses in humans.
Negative_regulation (inhibition) of thromboxane B2 in PGE2
18) Confidence 0.03 Published 2005 Journal Rheumatology (Oxford) Section Abstract Doc Link 15855183 Disease Relevance 0.25 Pain Relevance 0.50
In contrast, inhibition of TXA2-dependent platelet function in vivo occurs when platelet COX-1-dependent capacity to synthesize TXA2 (as assessed by measuring serum TXB2 levels) is reduced ?
Negative_regulation (inhibition) of TXA2 in platelet
19) Confidence 0.02 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621416 Disease Relevance 0.35 Pain Relevance 0.35
In fact, a non-linear relationship of inhibition of platelet TXA2 generation with inhibition of TXA2-mediated platelet aggregation has been found (Sciulli et al 2006).
Negative_regulation (inhibition) of TXA2 in platelet
20) Confidence 0.02 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2621416 Disease Relevance 0.26 Pain Relevance 0.36

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox